Literature DB >> 18040842

WIN55,212-2-mediated inhibition of HIV-1 expression in microglial cells: involvement of cannabinoid receptors.

R Bryan Rock1, Genya Gekker, Shuxian Hu, Wen S Sheng, Guy A Cabral, Billy R Martin, Phillip K Peterson.   

Abstract

Cannabinoid receptors CB(1) and CB(2) are primarily expressed in cells of the nervous and immune systems, respectively. Recently, the synthetic CB(1)/CB(2) agonist WIN55,212-2 was found to suppress replication of HIV-1 in microglial cell cultures. The present study was undertaken to test the hypothesis that WIN55,212-2's antiviral effect is mediated via CB(2) receptors. By reverse transcription-polymerase chain reaction, microglia were found to express both CB(1) and CB(2) receptors. Using additional CB(1)/CB(2) receptor agonists and selective antagonists, we found that CB(2) receptors are involved in WIN55,212-2's antiviral activity and surprisingly that the CB(1) receptor-selective antagonist SR141716A behaved as an agonist in these brain macrophages.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 18040842     DOI: 10.1007/s11481-006-9040-4

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  18 in total

1.  Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells.

Authors:  R A Puffenbarger; A C Boothe; G A Cabral
Journal:  Glia       Date:  2000-01-01       Impact factor: 7.452

Review 2.  Pharmacology of cannabinoid CB1 and CB2 receptors.

Authors:  R G Pertwee
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

3.  A beneficial aspect of a CB1 cannabinoid receptor antagonist: SR141716A is a potent inhibitor of macrophage infection by the intracellular pathogen Brucella suis.

Authors:  A Gross; A Terraza; J Marchant; M Bouaboula; S Ouahrani-Bettache; J P Liautard; P Casellas; J Dornand
Journal:  J Leukoc Biol       Date:  2000-03       Impact factor: 4.962

4.  Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage-like cells in relation to cell activation.

Authors:  S J Carlisle; F Marciano-Cabral; A Staab; C Ludwick; G A Cabral
Journal:  Int Immunopharmacol       Date:  2002-01       Impact factor: 4.932

5.  Morphine enhances HIV infection of human blood mononuclear phagocytes through modulation of beta-chemokines and CCR5 receptor.

Authors:  Chang-Jiang Guo; Yuan Li; Sha Tian; Xu Wang; Steven D Douglas; Wen-Zhe Ho
Journal:  J Investig Med       Date:  2002-11       Impact factor: 2.895

6.  Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor.

Authors:  Juha R Savinainen; Tarja Kokkola; Outi M H Salo; Antti Poso; Tomi Järvinen; Jarmo T Laitinen
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

7.  Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization.

Authors:  Imre Szabo; Michele A Wetzel; Ning Zhang; Amber D Steele; David E Kaminsky; Chongguang Chen; Lee-Yuan Liu-Chen; Filip Bednar; Earl E Henderson; O M Zack Howard; Joost J Oppenheim; Thomas J Rogers
Journal:  J Leukoc Biol       Date:  2003-09-12       Impact factor: 4.962

8.  Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor.

Authors:  Andis Klegeris; Christopher J Bissonnette; Patrick L McGeer
Journal:  Br J Pharmacol       Date:  2003-06       Impact factor: 8.739

9.  Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide.

Authors:  Fabrizio Facchinetti; Elda Del Giudice; Sara Furegato; Marzla Passarotto; Alberta Leon
Journal:  Glia       Date:  2003-01-15       Impact factor: 7.452

10.  Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation.

Authors:  Jared Ehrhart; Demian Obregon; Takashi Mori; Huayan Hou; Nan Sun; Yun Bai; Thomas Klein; Francisco Fernandez; Jun Tan; R Douglas Shytle
Journal:  J Neuroinflammation       Date:  2005-12-12       Impact factor: 8.322

View more
  28 in total

Review 1.  Cannabinoid neuroimmune modulation of SIV disease.

Authors:  Patricia E Molina; Angela Amedee; Nicole J LeCapitaine; Jovanny Zabaleta; Mahesh Mohan; Peter Winsauer; Curtis Vande Stouwe
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-10       Impact factor: 4.147

Review 2.  Cannabinoid administration attenuates the progression of simian immunodeficiency virus.

Authors:  Patricia E Molina; Peter Winsauer; Ping Zhang; Edith Walker; Leslie Birke; Angela Amedee; Curtis Vande Stouwe; Dana Troxclair; Robin McGoey; Kurt Varner; Lauri Byerley; Lynn LaMotte
Journal:  AIDS Res Hum Retroviruses       Date:  2010-11-23       Impact factor: 2.205

Review 3.  Drugs of abuse and HIV infection/replication: implications for mother-fetus transmission.

Authors:  Xu Wang; Wen-Zhe Ho
Journal:  Life Sci       Date:  2010-11-04       Impact factor: 5.037

4.  Chronic Δ-9-tetrahydrocannabinol administration increases lymphocyte CXCR4 expression in rhesus macaques.

Authors:  Nicole J LeCapitaine; Ping Zhang; Peter Winsauer; Edith Walker; Curtis Vande Stouwe; Constance Porretta; Patricia E Molina
Journal:  J Neuroimmune Pharmacol       Date:  2011-04-12       Impact factor: 4.147

5.  Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDS.

Authors:  Santhi Gorantla; Edward Makarov; Deepa Roy; Jennifer Finke-Dwyer; L Charles Murrin; Howard E Gendelman; Larisa Poluektova
Journal:  J Neuroimmune Pharmacol       Date:  2010-06-12       Impact factor: 4.147

6.  High-intensity cannabis use associated with lower plasma human immunodeficiency virus-1 RNA viral load among recently infected people who use injection drugs.

Authors:  M-J Milloy; Brandon Marshall; Thomas Kerr; Lindsey Richardson; Robert Hogg; Silvia Guillemi; Julio S G Montaner; Evan Wood
Journal:  Drug Alcohol Rev       Date:  2014-11-11

Review 7.  Immunomodulatory properties of kappa opioids and synthetic cannabinoids in HIV-1 neuropathogenesis.

Authors:  Shuxian Hu; Wen S Sheng; Robert Bryan Rock
Journal:  J Neuroimmune Pharmacol       Date:  2011-08-18       Impact factor: 4.147

Review 8.  Epigenetics, drugs of abuse, and the retroviral promoter.

Authors:  Jasmine Shirazi; Sonia Shah; Divya Sagar; Michael R Nonnemacher; Brian Wigdahl; Zafar K Khan; Pooja Jain
Journal:  J Neuroimmune Pharmacol       Date:  2013-11-12       Impact factor: 4.147

9.  Cannabinoid inhibition of macrophage migration to the trans-activating (Tat) protein of HIV-1 is linked to the CB(2) cannabinoid receptor.

Authors:  Erinn S Raborn; Guy A Cabral
Journal:  J Pharmacol Exp Ther       Date:  2010-01-20       Impact factor: 4.030

10.  Cannabinoid receptor-2 and HIV-associated neurocognitive disorders.

Authors:  Vishnudutt Purohit; Rao S Rapaka; Joni Rutter
Journal:  J Neuroimmune Pharmacol       Date:  2014-09       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.